COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer

NACompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Metastatic Colorectal Cancer
Interventions
OTHER

Blood analysis by EPISPOT and Cellsearch

For each patient, we will perform a counting of CTC before chemotherapy and then at different time points after chemotherapy, using both technologies: EPISPOT and CellSearch®.For the EPISPOT, we will need 15 mL of peripheral blood on EDTA tubes. For each patient, five blood samples will be done: D0, D14, D28, D42 and D56. These different time points will help us to determine when the best moment is for the evaluation of the CTC with this technology.For the CellSearch®, we will need 10 mL of peripheral blood on a specific CellSave tube. Only two samples will be perform: D0 and D28 because Cohen et al. (2008) reported that the best appropriated moment to appreciate the CTC progression is between 3 and 5 weeks after the initiation of the treatment.

Trial Locations (1)

34090

Medical Oncology, CHU St Eloi, Montpellier

All Listed Sponsors
collaborator

National Cancer Institute, France

OTHER_GOV

collaborator

Direction Générale de l'Offre de Soins

OTHER_GOV

collaborator

Roche Pharma AG

INDUSTRY

lead

University Hospital, Montpellier

OTHER

NCT01596790 - COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter